Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q6PK18
UPID:
OGFD3_HUMAN
Alternative names:
-
Alternative UPACC:
Q6PK18; C9JDC8; Q8IZ37; Q9H6J2
Background:
The 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 3, identified by the accession number Q6PK18, plays a crucial role in cellular processes through its enzymatic activities. This protein is involved in the hydroxylation of various substrates, a reaction essential for numerous metabolic pathways.
Therapeutic significance:
Understanding the role of 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 3 could open doors to potential therapeutic strategies. Its involvement in key biochemical pathways suggests its potential as a target for drug discovery, aiming to modulate its activity for therapeutic benefits.